BlackRock Inc. Makes New $1.20 Billion Investment in Elanco Animal Health Incorporated $ELAN

Key Points

• BlackRock acquired a new $1.20 billion stake in Elanco Animal Health, purchasing 48.85 million shares and becoming the owner of approximately 9.78% of the company. Institutional investors collectively own 97.48% of ELAN.
• Elanco reported quarterly revenue of $1.37 billion, up 10.2% year over year, while adjusted earnings of $0.34 per share exceeded analysts’ $0.27 estimate. The company issued third-quarter EPS guidance of $0.19–$0.22 and full-year guidance of $1.10–$1.16.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $29.09 versus the stock’s reported $24.05 price. Company insiders also purchased shares recently, including buys by the CFO and another insider.

BlackRock Inc. bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 48,849,973 shares of the company's stock, valued at approximately $1,202,198,000. BlackRock Inc. owned 9.78% of Elanco Animal Health as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Elanco Animal Health in the first quarter worth about $2,065,000. Goldman Sachs Group Inc. increased its position in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Empowered Funds LLC raised its stake in Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock valued at $166,000 after buying an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock worth $18,830,000 after acquiring an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Elanco Animal Health by 2,006.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company's stock valued at $4,432,000 after acquiring an additional 295,651 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

ELAN opened at $24.05 on Friday. Elanco Animal Health Incorporated has a twelve month low of $17.11 and a twelve month high of $27.98. The firm has a market capitalization of $12.02 billion, a PE ratio of -58.66, a PEG ratio of 1.41 and a beta of 1.67. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The firm's 50-day moving average price is $24.56 and its 200 day moving average price is $24.01.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period last year, the company posted $0.26 EPS. The business's revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ELAN shares. KeyCorp upped their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Wall Street Zen cut Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research note on Sunday, May 24th. JPMorgan Chase & Co. lifted their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, May 7th. Morgan Stanley upped their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 22nd. Finally, Piper Sandler reiterated an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and an average price target of $29.09.

Insider Activity

In other Elanco Animal Health news, insider Shiv O'neill purchased 3,998 shares of the stock in a transaction dated Tuesday, August 18th. The stock was acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the acquisition, the insider owned 87,832 shares in the company, valued at $2,071,078.56. This trade represents a 4.77% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $23.08 per share, with a total value of $96,936.00. Following the completion of the transaction, the chief financial officer directly owned 137,516 shares in the company, valued at approximately $3,173,869.28. The trade was a 3.15% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by company insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source